Antibody boost may help infants suppress HIV faster
NCT ID NCT07655141
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests whether adding two lab-made antibodies (ePGT121v1-LS and VRC07-523-LS) to standard antiretroviral therapy can help infants living with HIV achieve viral suppression. Infants up to one year old in Mozambique and Cameroon receive four injections of the antibodies or a placebo over 48 weeks. Researchers monitor safety, how the body processes the antibodies, and whether the combination leads to faster or more sustained viral suppression compared to standard treatment alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
broadly neutralizing antibodies (ePGT121v1-LS and VRC07-523-LS)
What this could lead to
If successful, this approach could help infants with HIV achieve viral suppression more quickly and reliably, potentially reducing long-term health complications.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply to all infants. The antibodies are given as injections, which may cause side effects or discomfort.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••